| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 University Department of Medicine and Department of Infectious Disease, Mater Adult Hospital, Brisbane, Australia
2 The Adult Cystic Fibrosis Unit, The Prince Charles Hospital, Brisbane, Australia
3 Department of Respiratory Medicine, Mater Adult Hospital, Brisbane, Australia
Correspondence to:
Correspondence to:
Ms S Seeney, University Department of Medicine, Mater Adult Hospital, South Brisbane, Australia 4101;
sseeney{at}mailbox.uq.edu.au
Background: Relentless chronic pulmonary inflammation is the major contributor to morbidity and mortality in patients with cystic fibrosis (CF). While immunomodulating therapies such as prednisolone and ibuprofen may be beneficial, their use is limited by side effects. Macrolides have immunomodulatory properties and long term use dramatically improves prognosis in diffuse panbronchiolitis, a condition with features in common with the lung disease of CF.
Methods: To determine if azithromycin (AZM) improves clinical parameters and reduces inflammation in patients with CF, a 3 month prospective randomised double blind, placebo controlled study of AZM (250 mg/day) was undertaken in adults with CF. Monthly assessment included lung function, weight, and quality of life (QOL). Blood and sputum collection assessed systemic inflammation and changes in bacterial flora. Respiratory exacerbations were treated according to the policy of the CF Unit.
Results: Sixty patients were recruited (29 men) of mean (SD) age 27.9 (6.5) years and initial forced expiratory volume in 1 second (FEV1) 56.6 (22.3)% predicted. FEV1% and forced vital capacity (FVC)% predicted were maintained in the AZM group while in the placebo group there was a mean (SE) decline of –3.62 (1.78)% (p=0.047) and –5.73 (1.66)% (p=0.001), respectively. Fewer courses of intravenous antibiotics were used in patients on AZM (0.37 v 1.13, p=0.016). Median C reactive protein (CRP) levels declined in the AZM group from 10 to 5.4 mg/ml but remained constant in the placebo group (p<0.001). QOL improved over time in patients on AZM and remained unchanged in those on placebo (p=0.035).
Conclusion: AZM in adults with CF significantly improved QOL, reduced CRP levels and the number of respiratory exacerbations, and reduced the rate of decline in lung function. Long term AZM may have a significant impact on morbidity and mortality in patients with CF. Further studies are required to define frequency of dosing and duration of benefit.
Keywords: cystic fibrosis; azithromycin
This article has been cited by other articles:
|
|
 |
|
  K J Mackerness, G R Jenkins, A Bush, and P J Jose Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum Thorax, July 1, 2008; 63(7): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Saavedra, A. D. Patterson, J. West, S. H. Randell, D. W. Riches, K. C. Malcolm, C. D. Cool, J. A. Nick, and C. A. Dinarello Abrogation of Anti-Inflammatory Transcription Factor LKLF in Neutrophil-Dominated Airways Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 679 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan Intensive Care Management of the Patient With Cystic Fibrosis J Intensive Care Med, May 1, 2008; 23(3): 159 - 177. [Abstract] [PDF]
|
|
|
|
 |
|
 B. S. Murphy, V. Sundareshan, T. J. Cory, D. Hayes Jr, M. I. Anstead, and D. J. Feola Azithromycin alters macrophage phenotype J. Antimicrob. Chemother., March 1, 2008; 61(3): 554 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Starner, J. D. Shrout, M. R. Parsek, P. C. Appelbaum, and G. Kim Subinhibitory Concentrations of Azithromycin Decrease Nontypeable Haemophilus influenzae Biofilm Formation and Diminish Established Biofilms Antimicrob. Agents Chemother., January 1, 2008; 52(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kohler, J.-L. Dumas, and C. Van Delden Ribosome Protection Prevents Azithromycin-Mediated Quorum-Sensing Modulation and Stationary-Phase Killing of Pseudomonas aeruginosa Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4243 - 4248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Flume, B. P. O'Sullivan, K. A. Robinson, C. H. Goss, P. J. Mogayzel Jr., D. B. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell, et al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 957 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hoffmann, B. Lee, M. Hentzer, T. B. Rasmussen, Z. Song, H. K. Johansen, M. Givskov, and N. Hoiby Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr / Mice Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3677 - 3687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McCormack, S. Bell, S. Senini, K. Walmsley, K. Patel, C. Wainwright, D. Serisier, M. Harris, and S. Bowler Daily versus weekly azithromycin in cystic fibrosis patients Eur. Respir. J., September 1, 2007; 30(3): 487 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mayer-Hamblett, B. W. Ramsey, and R. A. Kronmal Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis Proceedings of the ATS, August 1, 2007; 4(4): 370 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C Bell and P. J Robinson Exacerbations in cystic fibrosis: 2 {middle dot} Prevention Thorax, August 1, 2007; 62(8): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J S Elborn and S C Bell Pulmonary exacerbations in cystic fibrosis and bronchiectasis Thorax, April 1, 2007; 62(4): 288 - 290. [Full Text] [PDF]
|
|
|
|
|
|
C. Cigana, B. M. Assael, and P. Melotti Azithromycin Selectively Reduces Tumor Necrosis Factor Alpha Levels in Cystic Fibrosis Airway Epithelial Cells Antimicrob. Agents Chemother., March 1, 2007; 51(3): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Enderby and I. Doull Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success? Arch. Dis. Child., March 1, 2007; 92(3): 195 - 196. [Full Text] [PDF]
|
|
|
|
|
|
J K Block, K L Vandemheen, E Tullis, D Fergusson, S Doucette, D Haase, Y Berthiaume, N Brown, P Wilcox, P Bye, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria Thorax, November 1, 2006; 61(11): 969 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Clement, A Tamalet, E Leroux, S Ravilly, B Fauroux, and J-P Jais Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial Thorax, October 1, 2006; 61(10): 895 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nalca, L. Jansch, F. Bredenbruch, R. Geffers, J. Buer, and S. Haussler Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1680 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Asgrimsson, T. Gudjonsson, G. H. Gudmundsson, and O. Baldursson Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1805 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Little Treating Acute Asthma with Antibiotics -- Not Quite Yet N. Engl. J. Med., April 13, 2006; 354(15): 1632 - 1634. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Phaff, H. A. W. M. Tiddens, H. A. Verbrugh, and A. Ott Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis J. Antimicrob. Chemother., April 1, 2006; 57(4): 741 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Serisier, J. K. Shute, P. M. Hockey, B. Higgins, J. Conway, and M. P. Carroll Inhaled heparin in cystic fibrosis Eur. Respir. J., February 1, 2006; 27(2): 354 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Stover and D. Mangino Macrolides: A Treatment Alternative for Bronchiolitis Obliterans Organizing Pneumonia? Chest, November 1, 2005; 128(5): 3611 - 3617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Wilkes, T. M. Egan, and H. Y. Reynolds Lung Transplantation: Opportunities for Research and Clinical Advancement Am. J. Respir. Crit. Care Med., October 15, 2005; 172(8): 944 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Saiman, N. Mayer-Hamblett, P. Campbell, B. C. Marshall, and for the Macrolide Study Group Heterogeneity of Treatment Response to Azithromycin in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2005; 172(8): 1008 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hill, B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, B. Thompson, C. MacLeod, S. D. Aaron, et al. Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions J. Clin. Microbiol., October 1, 2005; 43(10): 5085 - 5090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gillis, K. G. White, K.-H. Choi, V. E. Wagner, H. P. Schweizer, and B. H. Iglewski Molecular Basis of Azithromycin-Resistant Pseudomonas aeruginosa Biofilms Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3858 - 3867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wagner, G. Soong, S. Sokol, L. Saiman, and A. Prince Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients Chest, August 1, 2005; 128(2): 912 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Bush How has research in the last five years changed my clinical practice? Arch. Dis. Child., August 1, 2005; 90(8): 832 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J S Parmar and S Nasser Antibiotic allergy in cystic fibrosis Thorax, June 1, 2005; 60(6): 517 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Barker, D. J. Gillie, M. S. Schechter, and B. K. Rubin Effect of Macrolides on In Vivo Ion Transport across Cystic Fibrosis Nasal Epithelium Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 868 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Kastelik, D. G. Peckham, and S. Conway Azithromycin in cystic fibrosis Eur. Respir. J., April 1, 2005; 25(4): 771 - 771. [Full Text] [PDF]
|
|
|
|
 |
|
 S C Bell, S L Senini, and J G McCormack Macrolides in cystic fibrosis Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98. [Abstract] [PDF]
|
|
|
|
|
|
M. Khalid, A. Al Saghir, S. Saleemi, S. Al Dammas, M. Zeitouni, A. Al Mobeireek, N. Chaudhry, and E. Sahovic Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study Eur. Respir. J., March 1, 2005; 25(3): 490 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Amsden Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother., January 1, 2005; 55(1): 10 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Voils, M. E Evans, M. T Lane, R. H Schosser, and R. P Rapp Use of Macrolides and Tetracyclines for Chronic Inflammatory Diseases Ann. Pharmacother., January 1, 2005; 39(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Tsai, M. L. Rodriguez, K. S. Young, J. C. Deng, V. J. Thannickal, K. Tateda, M. B. Hershenson, and T. J. Standiford Azithromycin Blocks Neutrophil Recruitment in Pseudomonas Endobronchial Infection Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1331 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gillis and B. H. Iglewski Azithromycin Retards Pseudomonas aeruginosa Biofilm Formation J. Clin. Microbiol., December 1, 2004; 42(12): 5842 - 5845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.W. Southern and P.M. Barker Azithromycin for cystic fibrosis Eur. Respir. J., November 1, 2004; 24(5): 834 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R Carr and M. C Nahata Azithromycin for Improving Pulmonary Function in Cystic Fibrosis Ann. Pharmacother., September 1, 2004; 38(9): 1520 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Schultz Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis J. Antimicrob. Chemother., July 1, 2004; 54(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nagata, H. Mukae, J. Kadota, T. Hayashi, T. Fujii, M. Kuroki, R. Shirai, K. Yanagihara, K. Tomono, T. Koji, et al. Effect of Erythromycin on Chronic Respiratory Infection Caused by Pseudomonas aeruginosa with Biofilm Formation in an Experimental Murine Model Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2251 - 2259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Davies and R Wilson Prophylactic antibiotic treatment of bronchiectasis with azithromycin Thorax, June 1, 2004; 59(6): 540 - 541. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Moskowitz, J. M. Foster, J. Emerson, and J. L. Burns Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis J. Clin. Microbiol., May 1, 2004; 42(5): 1915 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Rubin and M. O. Henke Immunomodulatory Activity and Effectiveness of Macrolides in Chronic Airway Disease Chest, February 1, 2004; 125(2_suppl): 70S - 78S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Favre-Bonte, T. Kohler, and C. Van Delden Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin J. Antimicrob. Chemother., October 1, 2003; 52(4): 598 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Saiman, B. C. Marshall, N. Mayer-Hamblett, J. L. Burns, A. L. Quittner, D. A. Cibene, S. Coquillette, A. Y. Fieberg, F. J. Accurso, and P. W. Campbell III Azithromycin in Patients With Cystic Fibrosis Chronically Infected With Pseudomonas aeruginosa: A Randomized Controlled Trial JAMA, October 1, 2003; 290(13): 1749 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Gerhardt, J. F. McDyer, R. E. Girgis, J. V. Conte, S. C. Yang, and J. B. Orens Maintenance Azithromycin Therapy for Bronchiolitis Obliterans Syndrome: Results of a Pilot Study Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 121 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Aaron, W. Ferris, K. Ramotar, K. Vandemheen, F. Chan, and R. Saginur Single and Combination Antibiotic Susceptibilities of Planktonic, Adherent, and Biofilm-Grown Pseudomonas aeruginosa Isolates Cultured from Sputa of Adults with Cystic Fibrosis J. Clin. Microbiol., November 1, 2002; 40(11): 4172 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D G Peckham Macrolide antibiotics and cystic fibrosis Thorax, March 1, 2002; 57(3): 189 - 190. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
